Article
Proteomic biomarkers for acute interstitial lung disease in gefitinib-treated Japanese lung cancer patients.
PloS one - 1 Jan 2011
Nyberg Fredrik, Ogiwara Atsushi, Harbron Chris G, Kawakami Takao, Nagasaka Keiko, Takami Sachiko, Wada Kazuya, Tu Hsiao-Kun, Otsuji Makiko, Kyono Yutaka, Dobashi Tae, Komatsu Yasuhiko, Kihara Makoto, Akimoto Shingo, Peers Ian S, South Marie C, Higenbottam Tim, Fukuoka Masahiro, Nakata Koichiro, Ohe Yuichiro, Kudoh Shoji, Clausen Ib Groth, Nishimura Toshihide, Marko-Varga György, Kato Harubumi
Abstract excerpt
Interstitial lung disease (ILD) events have been reported in Japanese non-small-cell lung cancer (NSCLC) patients receiving EGFR tyrosine kinase inhibitors. We investigated proteomic biomarkers for mechanistic insights and improved prediction of ILD. Blood plasma was collected from 43 gefitinib-treated NSCLC patients developing acute ILD (confirmed by blinded diagnostic review) and 123 randomly selected controls...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
